Risk of Heart Disease Following Treatment for Breast Cancer - Results from a Population-based Cohort Study

Overview

Journal Elife

Specialty Biology

Date 2022 Mar 16

PMID 35293856

Authors

Haomin Yang

Nirmala Bhoo-Pathy

Judith S Brand

Elham Hedayati

Felix Grassmann

Erwei Zeng

Jonas Bergh

Weiwei Bian

Jonas F Ludvigsson

Per Hall

Kamila Czene

Affiliations

Soon will be listed here.

Abstract

Background: There is a rising concern about treatment-associated cardiotoxicities in breast cancer patients. This study aimed to determine the time- and treatment-specific incidence of arrhythmia, heart failure, and ischemic heart disease in women diagnosed with breast cancer.

Methods: A register-based matched cohort study was conducted including 8015 breast cancer patients diagnosed from 2001 to 2008 in the Stockholm-Gotland region and followed up until 2017. Time-dependent risks of arrhythmia, heart failure, and ischemic heart disease in breast cancer patients were assessed using flexible parametric models as compared to matched controls from general population. Treatment-specific effects were estimated in breast cancer patients using Cox model.

Results: Time-dependent analyses revealed long-term increased risks of arrhythmia and heart failure following breast cancer diagnosis. Hazard ratios (HRs) within the first year of diagnosis were 2.14 (95% CI = 1.63-2.81) for arrhythmia and 2.71 (95% CI = 1.70-4.33) for heart failure. HR more than 10 years following diagnosis was 1.42 (95% CI = 1.21-1.67) for arrhythmia and 1.28 (95% CI = 1.03-1.59) for heart failure. The risk for ischemic heart disease was significantly increased only during the first year after diagnosis (HR = 1.45, 95% CI = 1.03-2.04). Trastuzumab and anthracyclines were associated with increased risk of heart failure. Aromatase inhibitors, but not tamoxifen, were associated with risk of ischemic heart disease. No increased risk of heart disease was identified following locoregional radiotherapy.

Conclusions: Administration of systemic adjuvant therapies appears to be associated with increased risks of heart disease. The risk estimates observed in this study may aid adjuvant therapy decision-making and patient counseling in oncology practices.

Funding: This work was supported by the Swedish Research Council (grant no: 2018-02547); Swedish Cancer Society (grant no: CAN-19-0266); and FORTE (grant no: 2016-00081).

Citing Articles

A meta-analysis on the impact of concurrent or pre-existing cancer diagnosis on acute myocardial infarction outcomes.

Wang J, Yu J PLoS One. 2025; 20(1):e0318437.

PMID: 39888923 PMC: 11785289. DOI: 10.1371/journal.pone.0318437.

Physical activity and incident cardiovascular disease in breast cancer survivors: the Pathways Study.

Kresovich J, Richards A, Ergas I, Cannioto R, Thomsen C, Laurent C JNCI Cancer Spectr. 2024; 9(1).

PMID: 39693117 PMC: 11737308. DOI: 10.1093/jncics/pkae123.

Dose advantage of abdominal deep inspiratory breath-hold (aDIBH) in postoperative adjuvant radiotherapy for left breast cancer.

Lai J, Luo H, Hu S, Zhong F, Chen R, Lin H J Egypt Natl Canc Inst. 2024; 36(1):29.

PMID: 39307905 DOI: 10.1186/s43046-024-00234-2.

Associations of age at diagnosis of breast cancer with incident myocardial infarction and heart failure: A prospective cohort study.

Liang J, Pan Y, Zhang W, Gao D, Wang Y, Xie W Elife. 2024; 13.

PMID: 39172036 PMC: 11341089. DOI: 10.7554/eLife.95901.

Can heart failure phenotypes be predicted by cardiac remodelling peripartum or postpartum?.

Agarwal M, Leeson P, Kitt J Front Cardiovasc Med. 2024; 11:1409183.

PMID: 39165262 PMC: 11333610. DOI: 10.3389/fcvm.2024.1409183.

References

Papakonstantinou A, Matikas A, Bengtsson N, Malmstrom P, Hedayati E, Steger G . Efficacy and safety of tailored and dose-dense adjuvant chemotherapy and trastuzumab for resected HER2-positive breast cancer: Results from the phase 3 PANTHER trial. Cancer. 2019; 126(6):1175-1182. DOI: 10.1002/cncr.32653. View

Taylor C, Kirby A . Cardiac Side-effects From Breast Cancer Radiotherapy. Clin Oncol (R Coll Radiol). 2015; 27(11):621-9. DOI: 10.1016/j.clon.2015.06.007. View

. Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials. Lancet. 2015; 386(10001):1341-1352. DOI: 10.1016/S0140-6736(15)61074-1. View

Cameron D, Piccart-Gebhart M, Gelber R, Procter M, Goldhirsch A, de Azambuja E . 11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial. Lancet. 2017; 389(10075):1195-1205. PMC: 5465633. DOI: 10.1016/S0140-6736(16)32616-2. View

Charlson M, Pompei P, Ales K, MacKenzie C . A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987; 40(5):373-83. DOI: 10.1016/0021-9681(87)90171-8. View

Grazette L, Boecker W, Matsui T, Semigran M, Force T, Hajjar R . Inhibition of ErbB2 causes mitochondrial dysfunction in cardiomyocytes: implications for herceptin-induced cardiomyopathy. J Am Coll Cardiol. 2004; 44(11):2231-8. DOI: 10.1016/j.jacc.2004.08.066. View

Colzani E, Liljegren A, Johansson A, Adolfsson J, Hellborg H, Hall P . Prognosis of patients with breast cancer: causes of death and effects of time since diagnosis, age, and tumor characteristics. J Clin Oncol. 2011; 29(30):4014-21. DOI: 10.1200/JCO.2010.32.6462. View

Navi B, Reiner A, Kamel H, Iadecola C, Okin P, Elkind M . Risk of Arterial Thromboembolism in Patients With Cancer. J Am Coll Cardiol. 2017; 70(8):926-938. PMC: 5667567. DOI: 10.1016/j.jacc.2017.06.047. View

Harris E, Correa C, Hwang W, Liao J, Litt H, Ferrari V . Late cardiac mortality and morbidity in early-stage breast cancer patients after breast-conservation treatment. J Clin Oncol. 2006; 24(25):4100-6. DOI: 10.1200/JCO.2005.05.1037. View

10.

Lyu Y, Kerrigan J, Lin C, Azarova A, Tsai Y, Ban Y . Topoisomerase IIbeta mediated DNA double-strand breaks: implications in doxorubicin cardiotoxicity and prevention by dexrazoxane. Cancer Res. 2007; 67(18):8839-46. DOI: 10.1158/0008-5472.CAN-07-1649. View

11.

Hammar N, Alfredsson L, Rosen M, Spetz C, Kahan T, Ysberg A . A national record linkage to study acute myocardial infarction incidence and case fatality in Sweden. Int J Epidemiol. 2002; 30 Suppl 1:S30-4. DOI: 10.1093/ije/30.suppl_1.s30. View

12.

Chen T, Xu T, Li Y, Liang C, Chen J, Lu Y . Risk of cardiac dysfunction with trastuzumab in breast cancer patients: a meta-analysis. Cancer Treat Rev. 2010; 37(4):312-20. DOI: 10.1016/j.ctrv.2010.09.001. View

13.

Foukakis T, von Minckwitz G, Bengtsson N, Brandberg Y, Wallberg B, Fornander T . Effect of Tailored Dose-Dense Chemotherapy vs Standard 3-Weekly Adjuvant Chemotherapy on Recurrence-Free Survival Among Women With High-Risk Early Breast Cancer: A Randomized Clinical Trial. JAMA. 2016; 316(18):1888-1896. DOI: 10.1001/jama.2016.15865. View

14.

Boekel N, Schaapveld M, Gietema J, Rutgers E, Versteegh M, Visser O . Cardiovascular morbidity and mortality after treatment for ductal carcinoma in situ of the breast. J Natl Cancer Inst. 2014; 106(8). PMC: 4151854. DOI: 10.1093/jnci/dju156. View

15.

. Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials. Lancet. 2019; 393(10179):1440-1452. PMC: 6451189. DOI: 10.1016/S0140-6736(18)33137-4. View

16.

Du X, Xia R, Liu C, Cormier J, Xing Y, Hardy D . Cardiac toxicity associated with anthracycline-containing chemotherapy in older women with breast cancer. Cancer. 2009; 115(22):5296-308. DOI: 10.1002/cncr.24621. View

17.

Gervaso L, Dave H, Khorana A . Venous and Arterial Thromboembolism in Patients With Cancer: : State-of-the-Art Review. JACC CardioOncol. 2021; 3(2):173-190. PMC: 8352228. DOI: 10.1016/j.jaccao.2021.03.001. View

18.

Okoth K, Chandan J, Marshall T, Thangaratinam S, Neil Thomas G, Nirantharakumar K . Association between the reproductive health of young women and cardiovascular disease in later life: umbrella review. BMJ. 2020; 371:m3502. PMC: 7537472. DOI: 10.1136/bmj.m3502. View

19.

Wigertz A, Ahlgren J, Holmqvist M, Fornander T, Adolfsson J, Lindman H . Adherence and discontinuation of adjuvant hormonal therapy in breast cancer patients: a population-based study. Breast Cancer Res Treat. 2012; 133(1):367-73. DOI: 10.1007/s10549-012-1961-4. View

20.

Chavez-MacGregor M, Zhang N, Buchholz T, Zhang Y, Niu J, Elting L . Trastuzumab-related cardiotoxicity among older patients with breast cancer. J Clin Oncol. 2013; 31(33):4222-8. PMC: 3821011. DOI: 10.1200/JCO.2013.48.7884. View